Wize Pharma Inc is a reputable company that upholds strong values and embodies a comprehensive corporate philosophy. With a steadfast commitment to excellence, Wize Pharma Inc prioritizes integrity, innovation, and accountability. This pharmaceutical company strives to deliver high-quality products and services to meet the ever-evolving needs of their customers. Through a continuous pursuit of knowledge and advancement, Wize Pharma Inc ensures the utmost satisfaction of their stakeholders. By incorporating ethical business practices and promoting transparency, this esteemed company establishes trust and credibility within the industry. Wize Pharma Inc remains dedicated to improving healthcare outcomes and enhancing the overall well-being of individuals worldwide.

Wize Pharma Inc is primarily present in the United States, Israel, and China.

Since its inception, Wize Pharma Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for LO2A, its leading ophthalmic solution for the treatment of Dry Eye Syndrome (DES). In addition, Wize Pharma Inc established distribution agreements in various markets, expanding the global accessibility of LO2A. Furthermore, the company initiated clinical trials to evaluate LO2A's potential in treating other eye-related conditions. These achievements demonstrate Wize Pharma Inc's commitment to developing innovative solutions and expanding its presence in the ophthalmic market.

Wize Pharma Inc, founded in 1997, is a pharmaceutical company specializing in the development and commercialization of ophthalmic medications. Based in Israel, it focuses on innovative treatments for various ocular conditions, including dry eye syndrome. Wize Pharma Inc has a rich background of research and collaboration with renowned medical institutions to enhance its product portfolio. The company is dedicated to providing effective and safe solutions to improve eye health worldwide. With its commitment to research and development, Wize Pharma Inc continues to strive for advancements in ophthalmic therapeutics.

The main competitors of Wize Pharma Inc in the market include pharmaceutical companies such as Pfizer, Novartis, Johnson & Johnson, and Eli Lilly.

Wize Pharma Inc is primarily active in the healthcare industry.

Wize Pharma Inc is a pharmaceutical company that specializes in developing and commercializing ophthalmic medications. Their business model focuses on acquiring and licensing innovative ophthalmic drug products, conducting research and development, and seeking regulatory approvals. Wize Pharma Inc aims to meet the unmet medical needs in ophthalmology by improving existing therapeutic agents or developing new treatments for various eye disorders. Through strategic partnerships and collaborations, they strive to deliver cutting-edge solutions to the ophthalmic community and patients worldwide.

Rasio P/E Wize Pharma adalah -0,03.

Rasio KUV dari Wize Pharma adalah -0,00.

Skor Kualitas AlleAktien untuk Wize Pharma adalah 5/10.

Omset diharapkan Wize Pharma adalah -9.236,10 Brd. USD.

Laba diharapkan Wize Pharma adalah -486,32 Juta. USD.

Wize Pharma Inc is a company specialized in the development and marketing of medications. It focuses on eye diseases such as cataract, dry eye, and certain corneal diseases. The company is headquartered in Israel and is listed on the Tel Aviv Stock Exchange. Wize Pharma's business model is based on three main aspects: research, development, and marketing. The research department develops new active substances and technologies to find targeted therapeutic solutions for eye diseases. The development department is responsible for manufacturing active substances and medications based on the research results. Finally, marketing is done through the distribution of medications to doctors and pharmacies, as well as collaboration with partner companies. One of Wize Pharma's key products is the medication LO2A. It was specifically developed for the treatment of cataract and is approved in several countries, including Israel, the USA, and Canada. What makes LO2A unique is that it contains a natural substance called lanosterol, which studies have shown can prevent the formation of cataracts in the eyes. Another product in Wize Pharma's portfolio is the medication PLxGuard. It was developed specifically for the treatment of dry eye and contains Omega-3 fatty acids and Vitamin E, among other ingredients. PLxGuard is also approved in some countries and is marketed through the company's own distribution channel and partner companies. Wize Pharma emphasizes high quality and intensive collaboration with doctors and pharmacies in the marketing of its products. Regular training and continuing education are provided to healthcare professionals to keep them informed about the latest developments in the field of ophthalmology, enabling them to recommend the best possible therapy to their patients. Wize Pharma also maintains high quality standards and transparency in its collaboration with partner companies. Overall, Wize Pharma's business model is characterized by high innovation and a clear focus on the needs of patients with eye diseases. With the combination of research, development, and marketing, the company is well-positioned to continue its success and contribute to improving the health and quality of life for people with eye diseases.

Wize Pharma membayarkan dividen sebesar 0 USD yang dibagi melalui pembayaran dalam setahun.

Dividen untuk Wize Pharma saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari Wize Pharma adalah US97751M2070.

Ticker dari Wize Pharma adalah WIZP.

Dalam 12 bulan terakhir, Wize Pharma membayar dividen sebesar . Ini setara dengan yield dividen sekitar . Untuk 12 bulan mendatang, Wize Pharma diperkirakan akan membayar dividen sebesar 0 USD.

Imbal hasil dividen dari Wize Pharma saat ini adalah .

Wize Pharma membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

Wize Pharma membayar dividen setiap tahun dalam 0 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 USD. Ini setara dengan yield dividen sebesar 0 %.

Wize Pharma dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari Wize Pharma tanggal 30/12/2024 sejumlah 0 USD, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 30/12/2024.

Pembayaran dividen terakhir dilakukan pada 30/12/2024.

Pada tahun 2023, Wize Pharma 0 USD telah dibayarkan sebagai dividen.

Dividen dari Wize Pharma dibayarkan dalam USD.